potential COVID-19 treatments - versus remdesivir - for COVID 19 hospitalized pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.73 [0.37, 1.44]< 10%1 study (1/-)81.8 %NAnot evaluable crucial-
clinical improvement 0.79 [0.61, 1.02]> 10%1 study (1/-)3.3 %NAnot evaluable important-
clinical improvement (14-day) 1.53 [1.02, 2.29]> 10%1 study (1/-)98.0 %NAnot evaluable important-
clinical improvement (7-day) 1.46 [0.95, 2.23]> 10%1 study (1/-)95.8 %NAnot evaluable important-
clinical improvement (time to event analysis only) 0.79 [0.61, 1.02]> 10%1 study (1/-)3.3 %NAnot evaluable important-
recovery 0.81 [0.64, 1.03]> 10%1 study (1/-)4.4 %NAnot evaluable non important-

safety endpoints 00

serious adverse events (SAE), any 0.50 [0.32, 0.79]< 10%1 study (1/-)99.9 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.